Company Filing History:
Years Active: 2009-2021
Title: Maire Doyle: Innovator in Peptide Analog Research
Introduction
Maire Doyle is a prominent inventor based in Baltimore, MD (US), known for her significant contributions to the field of peptide analogs. With a total of 4 patents to her name, she has made remarkable strides in the development of innovative treatments for diabetes and neuroprotection.
Latest Patents
One of her latest patents focuses on GLP-1, exendin-4, and their peptide analogs. This invention relates to novel polypeptide analogs that are insulinotropic and long-acting. The polypeptide's insulinotropic effect is designed to be comparable to or exceed that of an equimolar amount of GLP-1 or exendin-4. Additionally, the invention outlines a method for treating diabetes by administering the polypeptide in an amount that has an insulinotropic effect. Furthermore, it explores the neuroprotective and neurotrophic effects of GLP-1, exendin-4, and their analogs.
Career Highlights
Maire Doyle is currently affiliated with the National Institutes of Health, a component of the US Department of Health & Human Services. Her work at this esteemed institution has allowed her to focus on groundbreaking research that has the potential to improve the lives of many individuals suffering from diabetes and related conditions.
Collaborations
Maire has collaborated with notable colleagues, including Nigel H Greig and Josephine M Egan, who have contributed to her research endeavors and the advancement of her innovative projects.
Conclusion
Maire Doyle's work in peptide analog research exemplifies her dedication to innovation in the medical field. Her patents and ongoing research continue to pave the way for new treatments that could significantly impact healthcare.